Varlitinib
- Generic Name
- Varlitinib
- Drug Type
- Small Molecule
- Chemical Formula
- C22H19ClN6O2S
- CAS Number
- 845272-21-1
- Unique Ingredient Identifier
- 846Y8197W1
- Background
Varlitinib is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 (Her-2/neu) and EGFR. Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients. Varlitinib has shown significant anti-tumor activity in preclinical models of human breast, lung, and epidermal carcinoma tumors.
- Indication
Investigated for use/treatment in cancer/tumors (unspecified).
Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab
Phase 2
Completed
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2017-10-17
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT02338245
- Locations
- 🇵🇭
Philippines, Dasmarinas, Philippines
🇸🇬Singapore, Singapore, Singapore
🇦🇺Australia, Western Australia, Australia
A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2
Phase 2
Completed
- Conditions
- Stomach NeoplasmsCancer of StomachGastric CancerCancer of the StomachGastric Neoplasms
- Interventions
- First Posted Date
- 2012-06-08
- Last Posted Date
- 2015-01-14
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT01614522
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath